medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2024, Número 3

Siguiente >>

Cardiovasc Metab Sci 2024; 35 (3)


La terrible epidemia que devasta México. Urge una cruzada nacional contra la aterosclerosis+

Rosas-Peralta M, Meaney E

Idioma: Inglés [English version]
Referencias bibliográficas: 51
Paginas: 82-88
Archivo PDF: 300.55 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. INEGI. Estadísticas de defunciones registradas (EDR) 2023 (preliminar). https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2024/EDR/EDR2023_ene-dic.pdf

  2. Raghavan S, Vassy JL, Ho YL, Song RJ, Gagnon DR, Cho K et al. Diabetes mellitus–related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019; 8: e011295. DOI: 10.1161/JAHA.118.011295.

  3. Cui J, Liu Y, Li Y, Xu F, Liu Y. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Front Cardiovasc Med. 2021; 8: 644189. https://doi.org/10.3389/fcvm.2021.644189.

  4. Campos-Nonato I, Galván-Valencia O, Hernández-Barrera L, Oviedo-Solís C, Barquera S. Prevalence of obesity and associated risk factors in Mexican adults: results of the Ensanut 2022. Salud Publica Mex. 2023; 65 (supl 1): S238-S247. https://doi.org/10.21149/14809.

  5. Shamah-Levy T, Gaona-Pineda EB, Cuevas-Nasu L, Morales-Ruan C, Valenzuela-Bravo DG, Méndez-Gómez Humarán I et al. Prevalence of overweight and obesity in Mexican school-aged children and adolescents. Ensanut 2020-2022. Salud Publica Mex. 2023; 65 (supl 1): S218-S224. https://doi.org/10.21149/14762.

  6. Martínez-Sánchez C, Arias-Mendoza A, González-Pacheco H, Araiza Garaygordobil D, Marroquín Donday LA, Padilla-Ibarra J et al. Reperfusion therapy of myocardial infarction in Mexico: A challenge for modern cardiology. Arch Cardiol Mex. 2017; 87: 144-150. doi: 10.1016/j.acmx.2016.12.007.

  7. Barquera S, Campos-Nonato I, Aguilar-Salinas C, Lopez-Ridaura R, Arredondo A, Rivera-Dommarco J. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health. 2013; 9: 3. doi: 10.1186/1744-8603-9-3.

  8. Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: Pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia. Int J Mol Sci. 2023; 24: 75. doi: 10.3390/ijms24010075.

  9. Linton MRF, Yancey PG, Davies SS, Gray Jerome W, Linton EF, Song WL et al. The role of lipids and lipoproteins in atherosclerosis. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E et al (editors). Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK343489/.

  10. Kounatidis D, Vallianou NG, Poulaki A, Evangelopoulos A, Panagopoulos F, Stratigou T. ApoB100 and atherosclerosis: What's new in the 21st Century? Metabolites. 2024; 14: 123. doi: 10.3390/metabo14020123.

  11. Gidding SS, Allen NB. Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem. J Am Heart Assoc. 2019; 8: e012924. doi: 10.1161/JAHA.119.012924.

  12. Meaney A, Martínez-Marroquín MY, Samaniego-Méndez V, Fernández-Barros C, Hidalgo I, Nájera N et al. In search of an appropriate risk scale for Mexicans. The insufficiencies of the Globorisk scale. Cardiovasc Metab Sci. 2024; 35: 6-15. https://dx.doi.org/10.35366/114999.

  13. Saadatagah S, Pasha AK, Alhalabi L, Sandhyavenu H, Farwati M, Smith CY et al. Coronary heart disease risk associated with primary isolated hypertriglyceridemia; population?based study. J Am Heart Assoc. 2021; 10: e019343. doi: 10.1161/JAHA.120.019343.

  14. Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: an update. Arch Cardiovasc Dis. 2021; 114: 132-139. doi: 10.1016/j.acvd.2020.11.006.

  15. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S et al. Triglycerides and the risk of coronary heart disease. 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation. 2007; 115: 450-458. https://doi. org/10.1161/CIRCULATIONAHA.106.637793.

  16. Sirtori CR, Calabresi L, Franceschini G, Baldassarre D, Amato M, Johansson J et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation. 2001; 103: 1949-1954. doi: 10.1161/01.cir.103.15.1949. PMID: 11306522.

  17. G HB, Rao VS, Kakkar VV. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute–phase response. Cholesterol. 2011; 2011: 274629. http://dx.doi.org/10.1155/2011/274629.

  18. Tall AR, Rader DJ. Trials and tribulations of CETP Inhibitors. Circ Res. 2018; 122: 106-112. doi: 10.1161/CIRCRESAHA.117.311978.

  19. Rivas-Gomez B, Almeda-Valdés P, Tussié-Luna MT, Aguilar-Salinas CA. Dyslipidemia in Mexico, a call for action. Rev Invest Clin. 2018; 70: 211-216. doi: 10.24875/RIC.18002573.

  20. Meaney A, Ceballos-Reyes G, Gutiérrez-Salmean G, Samaniego-Méndez V, Vela-Huerta A, Alcocer L et al. Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista study. Baseline data. Arch Cardiol Mex. 2013; 83: 249-256. doi: 10.1016/j.acmx.2013.05.002.

  21. Meaney E, Pérez-Robles E, Ortiz-Flores M, Pérez-Ishiwara G, Meaney A, Munguía L et al. Overweight, obesity, and age are the main determinants of cardiovascular risk aggregation in the current Mexican population: The FRIMEX III Study. J Clin Med. 2024; 13: 2248. doi: 10.3390/jcm13082248.

  22. Lorenzatti A, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol Rev. 2020; 15: e04. https://doi.org/10.15420/ecr.2019.06.

  23. Vinik AI. The metabolic basis of atherogenic dyslipidemia. Clin Cornerstone. 2005; 7: 27-35. doi: 10.1016/s1098-3597(05)80065-1.

  24. Assmann G, Schulte H. The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J. 1988; 116: 1713-1724. doi: 10.1016/0002-8703(88)90220-7.

  25. Estrada-García T, Meaney A, López-Hernández D, Meaney E, Sánchez-Hernández O, Rodríguez-Arellano E et al. Hypertension and lipid triad are the most important attributable risks for myocardial infarction in a middle class urban Mexican population. Ann Nutr Metab. 2013; 63 (s1): 1343 (Abstract).

  26. Bhatia HS, Wilkinson MJ. Lipoprotein(a): evidence for role as a causal risk factor in cardiovascular disease and emerging therapies. J Clin Med. 2022; 11: 6040. doi: 10.3390/jcm11206040.

  27. Dentali F, Gessi V, Marcucci R, Gianni M, Grandi AM, Franchini M. Lipoprotein(a) as a risk factor for venous thromboembolism: A systematic review and meta-analysis of the literature. Semin Thromb Hemost. 2017; 43: 614-620. doi: 10.1055/s-0036-1598002.

  28. Cardoso-Saldaña GC, González-Salazar María del C, Posadas-Sánchez R, Vargas-Alarcón G. Síndrome metabólico, lipoproteína(a) y aterosclerosis subclínica en población mexicana. Arch Cardio Méx. 2021; 91: 307-314. doi: 10.24875/acm.20000276.

  29. Cardoso-Saldaña GC, Posadas-Sánchez R, González-Salazar MDC, Fragoso-Lona JM, Vargas-Alarcón G. Coronary artery calcium is associated with LPA gene variant RS7765803-C in Mexican mestizo population. The GEA project. Rev Invest Clin. 2020; 72 (2): 61-68. doi: 10.24875/RIC.19003138.

  30. Cardoso-Saldaña G, Fragoso JM, Lale-Farjat S, Torres-Tamayo M, Posadas-Romero C, Vargas-Alarcón G et al. The rs10455872-G allele of the LPA gene is associated with high lipoprotein(a) levels and increased aortic valve calcium in a Mexican adult population. Genet Mol Biol. 2019; 42: 519-525. doi: 10.1590/1678-4685-GMB-2017-0371.19.

  31. De Los Ríos-Ibarra MO, Leiva-Pons JL, Rodríguez-Reyes H, Alcocer-Gamba MA, Cortés-Lawrenz J, Vizcaíno-Rios FM et al. Risk stratification and lipid evaluation in Mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The Mexican registry of cardiovascular diseases (REMECAR group). Atheroscler Plus. 2022; 50: 32-39. doi: 10.1016/j.athplu.2022.08.002.

  32. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42: 2439-2454. doi: 10.1093/eurheartj/ehab309.

  33. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42: 2455-2467. doi: 10.1093/eurheartj/ehab312.

  34. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 129 (Suppl. S2): S49-S73. doi: 10.1161/01.cir.0000437741.48606.98.

  35. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015; 3: 339-355. doi: 10.1016/S2213-8587(15)00081-9.

  36. Martínez-Marroquín Y, Meaney A, Samaniego-Méndez V, Nájera N, Ceballos G, Fernández-Barros C et al. The TG/HDL-c lipid ratio as a cardiovascular risk marker in a Mexican urban middle-class population: Do we need a risk score tailored for Mexicans? J Clin Med. 2023;12: 6005. doi: 10.3390/jcm12186005.

  37. OECD. Health spending. https://www.oecd.org/en/data/indicators/health-spending.html

  38. Statista. Healthcare expenditure as percentage of gross domestic product (GDP) in Latin America and the Caribbean in 2021, by country. https://www.statista.com/statistics/899278/latin-america-health-expenditure-share-gdp-country/#statisticContainer.

  39. INEGI. Cuenta satélite del sector salud de México (CSSSM) 2022. https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2023/CSSSM/CSSSM2022.pdf

  40. London School of Hygiene and Tropical Medicine. Resyst. A target for UHC: How much should governments spend on health? https://resyst.lshtm.ac.uk/

  41. International Monetary Fund. https://www.imf.org/external/datamapper/NGDPD@WEO/OEMDC/ADVEC/WEOWORLD/CHN.

  42. White M, Barquera S. Mexico adopts food warning labels, why now? Health Syst Reform. 2020; 6 (1): e1752063. https://doi.org/10.1080/23288604.2020.1752063.

  43. Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017; 6: 187. https://doi.org/10.1007/s13679-017-0262-y

  44. Doehner W, Gerstein HC, Ried J, Jung H, Asbrand C, Hess S et al. Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. Eur Heart J. 2020; 41: 2668-2677. doi: 10.1093/eurheartj/ehaa293.

  45. Puska P, Jaini P. The North Karelia Project: prevention of cardiovascular disease in Finland through population-based lifestyle interventions. Am J Lifestyle Med. 2020; 14: 495-499. https://doi.org/10.1177/1559827620910981.

  46. Morales-Villegas EC, Yarleque C, Almeida ML. Management of hypertension and dyslipidemia in Mexico: Evidence, gaps, and approach. Arch Cardiol Mex. 2023; 93: 077-087. doi: 10.24875/ACM.21000330.

  47. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, De la Cruz-Góngora V, Rivera-Dommarco J et al. Prevalencia de diabetes y control glucémico en México: resultados nacionales 2018 y 2020. Salud Publica Mex. 2021; 63: 725-733. https://doi.org/10.21149/12842.

  48. Meaney E. High blood pressure: the ambushed raider. Introductory remarks. Cardiovasc Metab Sci. 2022; 33 (Suppl 3): s173-s178. https://dx.doi.org/10.35366/105181.

  49. Meaney E, Pérez-Robles E, Ortiz-Flores M, Perez-Ishiwara G, Meaney A, Munguía L et al. Overweight, obesity, and age are the main determinants of cardiovascular risk aggregation in the current Mexican population: The FRIMEX III study. J Clin Med. 2024; 13: 2248. doi: 10.3390/jcm13082248.

  50. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239. doi: 10.1161/01.CIR.0000133317.49796.0E.

  51. Klaic M, Kapp S, Hudson P, Chapman W, Denehy L, Story D et al. Implementability of healthcare interventions: an overview of reviews and development of a conceptual framework. Implement Sci. 2022; 17 (1): 10. https://doi.org/10.1186/s13012-021-01171-737.




2020     |     www.medigraphic.com